Introduction- Chemoradiation (CRT) in esophageal cancer as a definitive modality of treatment has shown an increasing trend of utilization over surgical modalities. Local failures after chemoradiotherapy have led to the concept of radiation dose escalation, but simultaneously it leads to the concerns of radiation related toxicities of strictures and fistulas. Considering this fact dose escalation with intraluminal brachytherapy seems and optimal option. The present study retrospectively analyzed the safety and efficacy of using ILBT as a boost after external beam radiotherapy.Materials and Methods- Records of patients with Esophageal Carcinoma (EC) registered in the radiotherapy department between December 2008 to June 2016 were retrospectivelyanalyzed. Data was collected on patient, tumor and treatment characteristics and patient outcomes. The toxicitieshematological or radiation-induced were documented. Theresponse assessment after treatment and survival parameters were analyzed. Univariate and multivariate analyses were done for survival parameters. Statistical significance was considered if p-value was less than 0.05.Results- A total of 69 patients were eligible for the present analysis. Male to female ratio 1.09:1, with median age of 60 years. The common primary side was the middle 1/3rd esophagus. The mean tumor length was 6.4cm and all patients had squamous cell carcinoma. EBRT dose of 59.4 Gy was received 94.2% of patients, 13 (18.8%) received ILRT radiotherapy with 6Gy in a single setting. The median concurrent chemotherapy administered were 5. Grade 3 and 4 acute hematological toxicities were seen in terms of anemia (7.2%), leucopenia (18.8%) and thrombocytopenia (1.4%). Stenosis was seen in 40.6% of patients among which only 13 patients required dilatation. Nine of the patients receiving intraluminal brachytherapy (ILBT) developed fistula. The compete response was better in ILBT group (84.61 vs 57.49%, p=0.07). The median overall survival for all patients was 15 months. Overall survival was increased in patients of ILBT group (41 months versus 12 months, p=0.005).Conclusion- ILBT has the advantage of high precision and avoidance of dose to critical structures which could be optimally used for dose escalation in patients of cancer esophagus.